Alginate-based microencapsulation as a strategy to improve the therapeutic potential of cannabidiolic acid

• Published in: International journal of pharmaceutics 2024-12, Vol.669, p.125076, Article 125076
• Main Authors: Antezana, Pablo E., Municoy, Sofía, Silva Sofrás, Fresia M., Bellino, Martín G., Evelson, Pablo, Desimone, Martín F.
• Format: Article
• Language: English
• Subjects: Alginate; Cannabis sativa oil; CBDA; Microcapsules; Microfluidics
• ISSN: 0378-5173; 1873-3476; 1873-3476
• DOI: 10.1016/j.ijpharm.2024.125076

[Display omitted] Cannabidiolic Acid (CBDA) is a promising natural compound with potent antioxidant, anti-inflammatory, and anti-emetic properties. Its antioxidant activity rivals that of vitamin E, while its anti-inflammatory effects are also remarkable. Additionally, CBDA has been shown to effectively reduce nausea and emetic attacks. As a more natural and water-soluble alternative to CBD, CBDA offers improved bioavailability and absorption. However, despite its promising potential, the development of effective CBDA delivery systems is still in its early stages. Among the various materials suitable for drug delivery, alginate is a widely used biopolymer due to its abundance and common availability in nature. This study aimed to develop an efficient CBDA delivery carrier using a microflow-dripping method to microencapsulate CBDA into alginate carriers (Alg-CBDA). The antioxidant, antimicrobial, and cytotoxicity properties of these Alg-CBDA capsules were then evaluated. Our results demonstrated that encapsulating CBDA within alginate capsules yielded a novel multifunctional biomaterial with prolonged antioxidant activity up to 72 h and antimicrobial activity against Gram-positive bacteria. Furthermore, the encapsulation process significantly reduced CBDA’s cytotoxicity, broadening its potential applications. To our knowledge, this is the first study demonstrating the advantages of CBDA within a drug delivery framework.